API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Also known as: Fhd-286, 2671128-05-3, Fhd286, 1h-pyrrole-3-carboxamide, n-((1s)-2-((4-(6-((2r,6s)-2,6-dimethyl-4-morpholinyl)-2-pyridinyl)-2-thiazolyl)amino)-1-(methoxymethyl)-2-oxoethyl)-1-(methylsulfonyl)-, Unii-qha5xla4sa, Gtpl11967

Molecular Formula

C₂₄H₃₀N₆O₆S₂

Molecular Weight

562.7 g/mol

InChI Key

JBLQNFBXKOAIHG-FCEWJHQRSA-N

FDA UNII

QHA5XLA4SA

BRG1/BRM Inhibitor FHD-286 is an orally bioavailable, allosteric, small molecule inhibitor of transcription activator BRG1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4; SMARCA4) and BRM (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2; SMARCA2), with potential antineoplastic activity. Upon oral administration, BRG1/BRM inhibitor FHD-286 targets, binds to, and inhibits the activity of BRG1 and/or BRM, the primary ATPase components and mutually exclusive subunits of the BRG1/BRM-associated factor (BAF) complexes. This may lead to the inhibition of the SWI/SNF chromatin remodeling complex, disrupt chromatin remodeling and gene expression, and result in the downregulation of oncogenic pathways and the inhibition of tumor cell proliferation. BAF is an important regulator of transcriptional programs and gene expression. Mutations in BAF or its transcription factor partners are found in certain diseases including cancers.

1 2D Structure

FHD-286

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[(2S)-1-[[4-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-2-yl]-1,3-thiazol-2-yl]amino]-3-methoxy-1-oxopropan-2-yl]-1-methylsulfonylpyrrole-3-carboxamide

2.1.2 InChI

InChI=1S/C24H30N6O6S2/c1-15-10-29(11-16(2)36-15)21-7-5-6-18(25-21)20-14-37-24(27-20)28-23(32)19(13-35-3)26-22(31)17-8-9-30(12-17)38(4,33)34/h5-9,12,14-16,19H,10-11,13H2,1-4H3,(H,26,31)(H,27,28,32)/t15-,16+,19-/m0/s1

2.1.3 InChI Key

JBLQNFBXKOAIHG-FCEWJHQRSA-N

2.1.4 Canonical SMILES

CC1CN(CC(O1)C)C2=CC=CC(=N2)C3=CSC(=N3)NC(=O)C(COC)NC(=O)C4=CN(C=C4)S(=O)(=O)C

2.1.5 Isomeric SMILES

C[C@@H]1CN(C[C@@H](O1)C)C2=CC=CC(=N2)C3=CSC(=N3)NC(=O)[C@H](COC)NC(=O)C4=CN(C=C4)S(=O)(=O)C

2.2 Other Identifiers

2.2.1 UNII

QHA5XLA4SA

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Fhd-286

2. 2671128-05-3

3. Fhd286

4. 1h-pyrrole-3-carboxamide, N-((1s)-2-((4-(6-((2r,6s)-2,6-dimethyl-4-morpholinyl)-2-pyridinyl)-2-thiazolyl)amino)-1-(methoxymethyl)-2-oxoethyl)-1-(methylsulfonyl)-

5. Unii-qha5xla4sa

6. Gtpl11967

7. Ex-a6082

8. Nsc840947

9. Nsc-840947

10. Hy-144835

11. Cs-0435579

12. F78342

13. N-((s)-1-(4-(6-((2s,6r)-2,6-dimethylmorpholino)pyridin-2-yl)thiazol-2-ylamino)-3-methoxy-1-oxopropan-2-yl)-1-(methylsulfonyl)-1h-pyrrole-3-carboxamide

14. N-[(2s)-1-[[4-[6-[(2s,6r)-2,6-dimethylmorpholin-4-yl]pyridin-2-yl]-1,3-thiazol-2-yl]amino]-3-methoxy-1-oxopropan-2-yl]-1-methylsulfonylpyrrole-3-carboxamide

2.4 Create Date

2021-11-10

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₃₀N₆O₆S₂
Molecular Weight	562.7 g/mol
XLogP3	1.3
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	9
Exact Mass	562.16682505 g/mol
Monoisotopic Mass	562.16682505 g/mol
Topological Polar Surface Area	181 Å²
Heavy Atom Count	38
Formal Charge	0
Complexity	926
Isotope Atom Count	0
Defined Atom Stereocenter Count	3
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1